Harvard-trained gastroenterologist Dr. Saurabh Sethi shared three science-backed beverages that can help reduce liver fat and support liver...

Akero Therapeutics stock surged nearly 20% today. Novo Nordisk announced it will acquire Akero for $4.7 billion in cash. The deal values Ak...

In India's bustling cities like Mumbai, a concerning trend emerges as fatty liver disease, now termed MASLD, quietly rises alongside diabet...

Dan Marino, the NFL legend, has publicly shared his battle with fatty liver disease, diagnosed in 2007. He emphasizes the importance of die...

Dan Marino, the Miami Dolphins Hall of Fame quarterback, disclosed that he has been managing liver disease through diet and exercise, with ...

Fatty liver disease is becoming one of the world’s fastest-growing health problems, often progressing silently until serious complications ...

A new study from the University of Birmingham suggests that people with non-alcoholic fatty liver disease (NAFLD) are three times more like...

Fatty liver disease, also known as steatotic liver disease, often develops silently and can progress to serious liver conditions like cirrh...

Fatty liver disease occurs when excess fat builds up in the liver, leading to potential long-term damage. It is classified into two main ty...

Fatty liver or Metabolic dysfunction-associated steatotic liver disease (MASLD), affecting one in three adults globally, is a growing healt...

Liver cancer: A recent Lancet study reveals that 60% of liver cancer cases are preventable, urging immediate action against rising obesity,...

Fatty liver disease, now medically known as MASLD, is becoming more common, especially among people who are overweight, diabetic, or have m...

Altimmune stock took a huge hit after its liver disease drug, pemvidutide, failed to show strong results in reducing fibrosis during a key ...

A new international study has found that over 15 million people across the US, UK, Germany, and France are unknowingly living with metaboli...

GSK is set to acquire efimosfermin, a promising liver disease drug, from Boston Pharmaceuticals for a potential $2 billion. The deal includ...

A latest study has shown promising results in people suffering from metabolic dysfunction-associated steatohepatitis (MASH), an advanced fo...

Zydus will enter a competitive field, with an FDA decision on CymaBay's PBC drug due in August. Gilead Sciences announced its acquisition o...